ClinicalTrials.gg

How we know

Every link on this study, and who decided it

The study on the left, the conditions and drugs this site links it to, and on each link the judgments that made or checked it, by day and by judge. The top row is the record itself: each new version seen since tracking began. Dashed lines are links the registry record does not make itself. Select a link to see everything judged on it, or a mark for one decision with its reason and evidence.

16 links0 made here, not in the record36 judgments2 judges (the rules as one: Rule based)1 record change seen
Claude Opus 5.5Rule basedRecord updated on ClinicalTrials.govReplaced, or read an older version
Oct 19Oct 26Nov 2Nov 9Nov 16TodayNCT02344472Detect V / CHEVENDO (Chemovs. Endo)Prof. Wolfgang JanniPhase 3 · active not recruitinRECORDThe record itselfVersions seen nightly since Sep 25, 2…›Nov 8 · ClinicalTrials.gov record · MeSH filing re-derivedMeSH filing re-derivedCONDITIONSBreast NeoplasmsThe registry's MeSH filing›As of now · Rule based · Main conditionMain conditionDRUGSPertuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 3 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · BackgroundBackground · establishedTrastuzumabIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundCapecitabineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundPaclitaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundVinorelbineIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundDocetaxelIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundExemestaneIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedLetrozoleIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundAnastrozoleIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · TestedNov 18 · Rule based · BackgroundTestedFulvestrantIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 10 · Claude Opus 5.5 · Background · optionNov 18 · Rule based · BackgroundBackground · optionRibociclibIntervention entry›Nov 2 · Claude Opus 5.5 · TestedNov 3 · Claude Opus 5.5 · Background · establishedNov 18 · Rule based · TestedBackground · establishedAlbumin-Bound PaclitaxelEntry “nab-Paclitaxel”, read by our n…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundEribulinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundLeuprolideEntry “leuprorelin”, read by our name…›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackgroundGoserelinIntervention entry›Nov 2 · Claude Opus 5.5 · BackgroundNov 18 · Rule based · BackgroundBackground

Times are in your time zone; a day marked “day only” kept no time. The graph scrolls sideways on a narrow screen; every mark is also in the list below.

Pertuzumab

From the registry record3 judgments on this link
Role in the study, from the registry to what was judged
RegistryEntry “pertuzumab”the record gives no role
→judged=agrees=agrees
How the 3 judgments split100%of judgments with a known value say Background · established
Background · 3

All judgments on this study

WhenLinkJudgeDecisionState
Nov 2PertuzumabClaude Opus 5.5BackgroundReplaced
Nov 2TrastuzumabClaude Opus 5.5BackgroundCurrent
Nov 2CapecitabineClaude Opus 5.5BackgroundCurrent
Nov 2PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2VinorelbineClaude Opus 5.5BackgroundCurrent
Nov 2DocetaxelClaude Opus 5.5BackgroundCurrent
Nov 2ExemestaneClaude Opus 5.5BackgroundReplaced
Nov 2LetrozoleClaude Opus 5.5BackgroundCurrent
Nov 2AnastrozoleClaude Opus 5.5BackgroundReplaced
Nov 2FulvestrantClaude Opus 5.5BackgroundReplaced
Nov 2RibociclibClaude Opus 5.5TestedReplaced
Nov 2Albumin-Bound PaclitaxelClaude Opus 5.5BackgroundCurrent
Nov 2EribulinClaude Opus 5.5BackgroundCurrent
Nov 2LeuprolideClaude Opus 5.5BackgroundCurrent
Nov 2GoserelinClaude Opus 5.5BackgroundCurrent
Nov 3PertuzumabClaude Opus 5.5Background · establishedCurrent
Nov 3RibociclibClaude Opus 5.5Background · establishedCurrent
Nov 8The record itselfClinicalTrials.gov recordMeSH filing re-derivedRecord change
Nov 10ExemestaneClaude Opus 5.5TestedCurrent
Nov 10AnastrozoleClaude Opus 5.5TestedCurrent
Nov 10FulvestrantClaude Opus 5.5Background · optionCurrent
Nov 18PertuzumabRule based · role ruleBackgroundAgrees
Nov 18TrastuzumabRule based · role ruleBackgroundAgrees
Nov 18CapecitabineRule based · role ruleBackgroundAgrees
Nov 18PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18VinorelbineRule based · role ruleBackgroundAgrees
Nov 18DocetaxelRule based · role ruleBackgroundAgrees
Nov 18ExemestaneRule based · role ruleBackgroundOverridden
Nov 18LetrozoleRule based · role ruleBackgroundAgrees
Nov 18AnastrozoleRule based · role ruleBackgroundOverridden
Nov 18FulvestrantRule based · role ruleBackgroundAgrees
Nov 18RibociclibRule based · role ruleTestedOverridden
Nov 18Albumin-Bound PaclitaxelRule based · role ruleBackgroundAgrees
Nov 18EribulinRule based · role ruleBackgroundAgrees
Nov 18LeuprolideRule based · role ruleBackgroundAgrees
Nov 18GoserelinRule based · role ruleBackgroundAgrees
As of nowBreast NeoplasmsRule based · main-condition ruleMain conditionCurrent

The rules, in plain words

“Rule based” means one of these decided, not a model or a person. Each runs every night over every study.

Which drugs a study tests

Reads each treatment the study lists and the arms it is in. A drug only in the experimental arm is tested. A drug in every arm while something else changes between the arms is given beside it. A drug only in the control arm is the comparator. Placebo, procedures and usual care are known by name.

Where the whole record has been read, that reading's answer replaces the rule's.

What a study is mainly about

Starts from the first condition ClinicalTrials.gov files the study under. It moves to a narrower one only when the study's own title or listed conditions name it, and sets aside terms the registry often files by mistake. A study open to many cancers is not placed under one of them unless its title names it.

Checked against studies judged one by one; the study page says when it differs from the registry.